The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ESH CLL 2022 | Managing CLL treatment in the future: targeted therapies and early intervention
Alberto Orfao, MD, PhD, University of Salamanca, Salamanca, Spain, highlights some important insights into the future of treating chronic lymphocytic leukemia (CLL), drawing focus on novel targeted therapies and early intervention. Dr Orfao first discusses the importance of better understanding mechanisms of altered survival in CLL and the use of novel, targeted therapies, such as BCL-2 inhibitors, Bruton’s tyrosine kinase (BTK) inhibitors, and chimeric antigen receptor T-cell (CAR-T) therapy. Dr Orfao then explains the importance of monitoring measurable residual disease (MRD) and monoclonal B-cell lymphocytosis (MBL) in the early stages to better anticipate therapy and implement early intervention in CLL treatment. This interview took place during the 2nd ESH Translational Research Conference on Chronic Lymphocytic Leukemia (ESH CLL), 2022.
